<DOC>
	<DOCNO>NCT01211522</DOCNO>
	<brief_summary>The long-term objective MIND-USA ( Modifying Impact ICU-Induced Neurological Dysfunction-USA ) Study define role antipsychotic management delirium vulnerable critically ill patient . We others show delirium independent predictor death , long stay , high cost , long-term cognitive impairment often commensurate moderate dementia . The rapidly expand age ICU population especially vulnerable develop delirium , 7 10 medical surgical ICU patient develop organ dysfunction . Antipsychotics first-line pharmacological agent recommend treat delirium , past 30 year gain widespread use hospitalize patient globally prior adequate test efficacy safety indication . Haloperidol , commonly choose antipsychotic , use 80 % ICU doctor delirium , atypical antipsychotic prescribe 40 % . Antipsychotics safety concern include lethal cardiac arrhythmia , extrapyramidal symptom , highly publicize increase mortality associate use non-ICU geriatric population . The overarch hypothesis administration typical atypical antipsychotics—haloperidol ziprasidone , case—to critically ill patient delirium improve short- long-term clinical outcome , include day alive without acute brain dysfunction ( refer delirium/coma-free day DCFDs ) 14-day period ; 30-day , 90-day , 1-year survival ; ICU length stay ; incidence , severity , and/or duration long-term neuropsychological dysfunction ; quality life 90-day 1-year . To test hypothesis , MIND-USA Study multi-center , double-blind , randomize , placebo-controlled investigation 561 critically ill , delirious medical/surgical ICU patient ( ) mechanical ventilation non-invasive positive pressure ventilation ( b ) shock vasopressor . In group ( haloperidol , ziprasidone , placebo ) , 187 patient enrol treated delirium resolve 48 hour 14 day ( whichever occurs first ) follow 1 year .</brief_summary>
	<brief_title>The Modifying Impact ICU-Associated Neurological Dysfunction-USA ( MIND-USA ) Study</brief_title>
	<detailed_description>The primary secondary outcome MIND-USA investigation analyze accord individual comparison group `` haloperidol treat '' vs. `` placebo treat '' `` ziprasidone treat '' vs. `` placebo treat '' also combine group antipsychotic ( `` haloperidol plus ziprasidone treat '' patient vs. `` placebo treat '' patient ) . In latter third study , result paper Patel S et al AJRCCM 2014 rapidly reversible delirium ( RRD ) , consider modify delirium assessment detect might convert CAM-ICU positive negative follow SATs , estimate 5 patient per arm would category ( indeed &lt; 20 per arm entire study use 10 % rate publish Patel ) . With low number assurance randomization would group analyze similarly accord study drug assignment , elect alter protocol conduct subgroup analyse accord RRD status .</detailed_description>
	<mesh_term>Delirium</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<criteria>1. adult patient ( ≥18 year old ) 2. medical and/or surgical ICU 3. mechanical ventilation noninvasive positive pressure ventilation ( NIPPV ) , and/or require vasopressor due shock 4. delirious ( accord CAMICU ) 1 . Rapidly resolve organ failure criterion , indicate plan immediate discontinuation mechanical ventilation , NIPPV , and/or vasopressor time screen study enrollment 2 . Pregnancy breastfeeding ( negative pregnancy test require prior enrollment female patient childbearing age ) 3 . Severe dementia neurodegenerative disease , define either impairment prevents patient live independently baseline IQCODE &gt; 4.5 , measure use patient 's qualified surrogate , mental illness require longterm institutionalization , acquire congenital mental retardation , Parkinson 's disease , Huntington 's disease , and/or coma another severe deficit due structural brain disease stroke , intracranial hemorrhage , cranial trauma , intracranial malignancy , anoxic brain injury , cerebral edema . 4 . History torsades de pointes , document baseline QT prolongation ( congenital long QT syndrome ) , QTc &gt; 500 m screen due refractory electrolyte abnormality , drug , thyroid disease 5 . Ongoing maintenance therapy typical atypical antipsychotic 6 . History neuroleptic malignant syndrome ( NMS ) , haloperidol allergy , ziprasidone allergy 7 . Expected death within 24 hour enrollment lack commitment aggressive treatment family medical team ( e.g. , likely withdrawal life support measure within 24 hour screen ) 8 . Inability obtain informed consent authorize representative within 72 hour meet inclusion criterion , i.e. , develop qualify organ dysfunction criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Delirium</keyword>
	<keyword>Intensive care</keyword>
	<keyword>Mechanical ventilation</keyword>
	<keyword>Antipsychotic</keyword>
	<keyword>Haloperidol</keyword>
	<keyword>Ziprasidone</keyword>
	<keyword>Randomized</keyword>
	<keyword>Placebo</keyword>
	<keyword>Sepsis</keyword>
	<keyword>Sedation</keyword>
	<keyword>Long-term cognitive impairment</keyword>
</DOC>